Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers


The solution


Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers.
We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.


News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Gate2Brain, beyond barriers. An interview by Oncobites

A novel technological platform for the delivery of therapeutics across biological barriers   Meritxell…

Bio-Europe 2023

Here, we are! Emerging from our enriching experience at Bio-Europe in Munich, where we were privileged…

Science Week 2023

This week, Gate2Brain ignited the spark of scientific wonder as our CEO, Meritxell Teixido , infused…

Inv€$tival Showcase – LSX

📅  Our Business Development Manager, Carles Taulé Flores, will be attending the 8th annual LSX…

Gate2Brain honored with an award as part of the EIT Health “Wild Card” program

Gate2Brain has recently been honored with an award as part of the EIT Health "Wild Card" program! What…

World Orphan Drug Congress Europe 2023

We're all geared up and excited for World Orphan Drug Congress Europe 2023❗❗ Gate2Brain is thrilled…

33rd Barcelona Investment Healthcare Forum

Gate2Brain, alongside 8 other health startups, is privileged to take part in the round presentations…

Finalist of EIT Health Wild Card Programme 2023

Gate2Brain has proudly earned a spot as a finalist in the esteemed 2023 EIT Health Wild Card Programme,…

G2B at Pediatric Diffuse Midline Glioma International Meeting

Gate2Brain was honored to participate in the Pediatric Diffuse Midline Glioma (DMG) International Meeting,…
BioSpain 2023G2B

BioSpain 2023

BioSpain was a whirlwind of activity! At #BioRegió, we were honored to receive a visit from Pere Aragonès,…

Making therapies a reality for patients by addressing unmet medical needs.


Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain